Murphy T J, Bylund D B
Department of Pharmacology, School of Medicine, University of Missouri-Columbia.
J Pharmacol Exp Ther. 1988 Feb;244(2):571-8.
We have characterized alpha-2 adrenergic receptors in OK cells, an opossum kidney-derived cell line. In membrane saturation binding experiments, [3H]rauwolscine (Kd = 74 pM) was 3-fold more potent than [3H]yohimbine (Kd = 230 pM). Each labeled a single class of binding sites with densities of 135 and 124 fmol/mg of protein for [3H]rauwolscine and [3H]yohimbine, respectively. Inhibition of [3H]rauwolscine and [3H]yohimbine binding by several alpha adrenergic agonists and antagonists demonstrated the radioligands labeled an alpha-2 type adrenergic receptor with a pharmacological profile similar to the alpha-2B receptor subtype. The rank order of potency for antagonist inhibition of binding was yohimbine greater than prazosin = phentolamine greater than chlorpromazine = corynanthine, whereas the rank order of agonist potency was oxymetazoline = clonidine greater than or equal to UK-14,304 greater than or equal to (-)-epinephrine greater than (-)-norepinephrine. The oxymetazoline, clonidine and antagonist inhibition curves were routinely monophasic and modeled best as a single class of binding sites. For the other agonists, inhibition binding curves were biphasic with approximately 35% of the binding sites existing in a high affinity state. These curves were shifted to the right in the presence of 0.1 mM GTP, and in general modeled as a single class of binding sites. UK-14,304, (-)-epinephrine, (-)-norepinephrine and oxymetazoline attenuated parathyroid hormone-stimulated cyclic AMP production by up to 70% in whole cell monolayers in a dose-dependent manner via a pertussis toxin-sensitive mechanism. With the exception of oxymetazoline, this inhibition could be reversed with alpha adrenergic antagonists.(ABSTRACT TRUNCATED AT 250 WORDS)
我们已对负鼠肾来源的细胞系OK细胞中的α-2肾上腺素能受体进行了特性描述。在膜饱和结合实验中,[3H]育亨宾(Kd = 74 pM)的效力比[3H]萝芙木碱(Kd = 230 pM)强3倍。[3H]萝芙木碱和[3H]育亨宾分别标记了单一类别的结合位点,蛋白质密度分别为135和124 fmol/mg。几种α肾上腺素能激动剂和拮抗剂对[3H]萝芙木碱和[3H]育亨宾结合的抑制作用表明,放射性配体标记的是α-2型肾上腺素能受体,其药理学特征与α-2B受体亚型相似。拮抗剂抑制结合的效力顺序为育亨宾>哌唑嗪 = 酚妥拉明>氯丙嗪 = 育亨烷,而激动剂效力顺序为羟甲唑啉 = 可乐定≥UK-14,304≥(-)-肾上腺素>(-)-去甲肾上腺素。羟甲唑啉、可乐定和拮抗剂的抑制曲线通常为单相,最适合模拟为单一类别的结合位点。对于其他激动剂,抑制结合曲线为双相,约35%的结合位点处于高亲和力状态。在0.1 mM GTP存在下,这些曲线向右移动,总体上模拟为单一类别的结合位点。UK-14,304、(-)-肾上腺素、(-)-去甲肾上腺素和羟甲唑啉通过百日咳毒素敏感机制,以剂量依赖方式使全细胞单层中甲状旁腺激素刺激的环磷酸腺苷生成减少高达70%。除羟甲唑啉外,这种抑制作用可用α肾上腺素能拮抗剂逆转。(摘要截断于250字)